{"id":"azacitidine-combined-hht","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression/neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azacitidine is a hypomethylating agent that reverses aberrant DNA methylation in myelodysplastic and hematologic malignancies, restoring expression of tumor suppressors. Homoharringtonine (HHT) is a natural alkaloid that inhibits translation elongation, triggering apoptosis particularly in leukemic blasts. The combination targets both epigenetic dysregulation and protein synthesis, providing complementary mechanisms against hematologic malignancies.","oneSentence":"Azacitidine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, while HHT (homoharringtonine) inhibits protein synthesis to induce apoptosis in leukemic cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:19.220Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"},{"name":"Myelodysplastic syndrome (MDS)"}]},"trialDetails":[{"nctId":"NCT05029141","phase":"PHASE2","title":"New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-09-01","conditions":"Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML","enrollment":21},{"nctId":"NCT07469046","phase":"PHASE3","title":"VAH vs VA in Newly Diagnosed Elderly AML","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2026-03-01","conditions":"Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years)","enrollment":308},{"nctId":"NCT06483906","phase":"PHASE2","title":"Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-07-02","conditions":"Acute Myeloid Leukemia","enrollment":56},{"nctId":"NCT04501120","phase":"PHASE1, PHASE2","title":"Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2020-09-28","conditions":"Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy","enrollment":458},{"nctId":"NCT07091006","phase":"PHASE2","title":"Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-08-01","conditions":"Relapse Leukemia","enrollment":44},{"nctId":"NCT06744556","phase":"PHASE2","title":"HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-01-21","conditions":"AML","enrollment":60},{"nctId":"NCT06810791","phase":"PHASE3","title":"HVA vs IA/DA or VA in the Treatment of ND HR-AML","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-01-01","conditions":"Newly Diagnosed Acute Myeloid Leukemia With High Risk","enrollment":876},{"nctId":"NCT06635681","phase":"PHASE2","title":"Efficacy of Venetoclax Combined with Intensive Chemotherapy in Different Subgroups of AML","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-09-29","conditions":"AML (Acute Myelogenous Leukemia)","enrollment":1200},{"nctId":"NCT06470841","phase":"PHASE2","title":"CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"Navy General Hospital, Beijing","startDate":"2024-09-20","conditions":"Acute Myeloid Leukemia","enrollment":85},{"nctId":"NCT06394011","phase":"PHASE2","title":"Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-02-15","conditions":"Intermediate Risk Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT04424147","phase":"PHASE2","title":"Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2020-05-27","conditions":"Refractory Acute Myeloid Leukemia, Relapsed Acute Erythroid Leukemia, Salvage Treatment","enrollment":96},{"nctId":"NCT05584761","phase":"PHASE1, PHASE2","title":"Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-03-01","conditions":"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia-2, Secondary Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT04248595","phase":"PHASE2","title":"Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML","status":"UNKNOWN","sponsor":"Ge Zheng","startDate":"2019-12-01","conditions":"Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT05513131","phase":"PHASE2","title":"Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-09-30","conditions":"Secondary Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT05457361","phase":"PHASE3","title":"VAH Versus VA for Salvage Therapy of R/R-AML","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2022-03-01","conditions":"Venetoclax Combined With Azacitidine Plus Homoharringtonine, Venetoclax Combined With Azacitidine","enrollment":162},{"nctId":"NCT05456048","phase":"","title":"Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-12-03","conditions":"Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Gene Abnormality","enrollment":231},{"nctId":"NCT03873311","phase":"PHASE4","title":"Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy","status":"UNKNOWN","sponsor":"Shenzhen Second People's Hospital","startDate":"2019-09-01","conditions":"Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia","enrollment":114},{"nctId":"NCT04722952","phase":"PHASE3","title":"PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-05-01","conditions":"Immunotherapy, Refractory Leukemia, Relapsed Adult AML","enrollment":30},{"nctId":"NCT04087967","phase":"PHASE3","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-04-01","conditions":"Acute Myeloid Leukemia, Induction Chemotherapy","enrollment":162},{"nctId":"NCT04083911","phase":"PHASE3","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-04-01","conditions":"Acute Myeloid Leukemia, Induction Chemotherapy","enrollment":50},{"nctId":"NCT03978364","phase":"PHASE3","title":"A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2019-06-01","conditions":"Myelodysplastic Syndromes,Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT02835794","phase":"PHASE1, PHASE2","title":"A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2016-08","conditions":"Myelodysplastic Syndromes","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Azacitidine+HHT"],"phase":"phase_3","status":"active","brandName":"Azacitidine combined HHT","genericName":"Azacitidine combined HHT","companyName":"Shandong Provincial Hospital","companyId":"shandong-provincial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azacitidine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, while HHT (homoharringtonine) inhibits protein synthesis to induce apoptosis in leukemic cells. Used for Acute myeloid leukemia (AML), Myelodysplastic syndrome (MDS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}